Investigational drugs in early development for treating dengue infection

References

• Pierson TC, Diamond MS. Flaviviruses. In: Knipe DM, Howley PM, editors. Fields virology. 6th ed. Philadelphia (PA): Wolters Kluwer and Lippincott Williams & Wilkins; 2013. p. 747–794.
   Google Scholar
• Kraemer MUG, Sinka ME, Duda KA, et al. The Global Distribution of the Arbovirus Vectors Aedes Aegypti and Ae. Albopictus. Elife. 2015;4:e08347.
   PubMed Web of Science ®Google Scholar
• Gubler DJ. The economic burden of dengue. Am J Trop Med Hyg. 2012;86:743–744.
   PubMed Web of Science ®Google Scholar
• Global strategy for dengue prevention and control. Geneva: World Health Organization; 2012. ISBN 978 92 4 150403 4.
   Google Scholar
• Guzman MG, Harris E. Dengue. Lancet. 2015;385:453–465.
   PubMed Web of Science ®Google Scholar
• Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496:504–507.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Batra G, Khanna N. Dengue vaccines: state of the art. Expert Opin Therap Patents. 2010;20:819–835.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Khanna N. Experimental dengue vaccines. In: Giese M, editor. Molecular vaccine-from prophylaxis to therapy. Heidelberg: Springer-Verlag; 2013. p. 135–151.
   Google Scholar
• Capeding MR, Tran NH, Hadinegoro SRS, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomized, observer-masked, placebo-controlled trial. Lancet. 2014;384:1358–1365.
   PubMed Web of Science ®Google Scholar
• Villar L, Dayan GH, Arredondo-García JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. New Eng J Med. 2015;372:113–123.
   PubMed Web of Science ®Google Scholar
• Beesetti H, Khanna N, Swaminathan S. Drugs for dengue: a patent review (2010–2014). Expert Opin Therap Patents. 2014;24:1174–1181.
   Web of Science ®Google Scholar
• Lim SP, Wang QY, Noble CG, et al. Ten years of dengue drug discovery: progress and prospects. Antiviral Res. 2013;100:500–519.
   PubMed Web of Science ®Google Scholar
• International Clinical Trials Registry Platform of the World Health Organization (URL: apps.who.int/trialsearch/)
   Google Scholar
• Dengue and dengue haemorrhagic fever. WHO Factsheet No117. 2014. Available from: www.who.int/mediacentre/factsheets/fs117/en/
   Google Scholar
• Lam P, Tam D, Diet T, et al. Clinical characteristics of dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital. Clin Infect Dis. 2013;57:1577–1586.
   PubMed Web of Science ®Google Scholar
• Simmons CP, Farrar JJ, Chau NV, et al. Dengue. N Engl J Med. 2012;366:1423–1432.
   PubMed Web of Science ®Google Scholar
• Vaughn DW, Greene S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000;181:2–9.
   PubMed Web of Science ®Google Scholar
• Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis. 2002;185:1213–1221.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Neutralization and antibody dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421–467.
   PubMed Web of Science ®Google Scholar
• Sierra B, Perez AB, Vogt K, et al. Secondary heterologous dengue infection risk: disequilibrium between immune regulation and inflammation?. Cell Immunol. 2010;262:134–140.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Khanna N. Dengue: recent advances in biology and current status of translational research. Curr Mol Med. 2009;9:152–173.
   PubMed Web of Science ®Google Scholar
• Shresta S, Sharar KL, Prigozhin DM, et al. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol. 2006;80:10208–10217.
   PubMed Web of Science ®Google Scholar
• Penn MS, Kamath M. Novel mechanisms for maintaining endothelial barrier function in sepsis. Circulation. 2012;126:2677–2679.
   PubMed Web of Science ®Google Scholar
• Wills BA, Oragui EE, Dung NM, et al. Size and charge characteristics of the protein leak in dengue shock syndrome. J Infect Dis. 2004;190:810–818.
   PubMed Web of Science ®Google Scholar
• Dengue guidelines for diagnosis, treatment, prevention and control. Geneva: World Health Organization; 2009. ISBN 978 92 4 154787 1.
   Google Scholar
• Whitehorn J, Yacoub S, Anders KL, et al. Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions. PLoS Negl Trop Dis. 2014;8:e3025.
   PubMed Web of Science ®Google Scholar
• Borges MC, Castro AL, Da Fonseca BAL. Chloroquine use improves dengue-related symptoms. Mem Inst Oswaldo Cruz. 2013;108:596–599.
   PubMed Web of Science ®Google Scholar
• Low JG, Sung C, Wijaya L, et al. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomized, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect Dis. 2014;14(8):706–715.
   PubMed Web of Science ®Google Scholar
• Nguyen THT, Nguyen THQ, Vu TT, et al. Corticosteroids for dengue – why don’t they work? PLoS Negl Trop Dis. 2013;7:e2592.
   PubMed Web of Science ®Google Scholar
• Nguyen NM, Tran CNB, Phung LK, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013;207:1442–1450.
   PubMed Web of Science ®Google Scholar
• Tam DTH, Ngoc TV, Tien NTH, et al. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infectious Dis. 2012;55:1216–1224.
   PubMed Web of Science ®Google Scholar
• Tricou V, Minh NN, Van TP, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis. 2010;4:e785.
   PubMed Web of Science ®Google Scholar
• Whitehorn J, Chau NVV, Truong NT, et al. Lovastatin for adult patients with dengue: protocol for a randomised controlled trial. BMC Trials. 2012;13:203.
   PubMed Web of Science ®Google Scholar
• Whitehorn J, Nguyen CVV, Khanh LP, et al. Lovastatin for the treatment of adult patients with dengue: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2015. doi:10.1093/cid/civ949.
   PubMed Web of Science ®Google Scholar
• NCBI PubChem compound database. Available from: https://pubchem.ncbi.nlm.nih.gov/.
   Google Scholar
• US NIH Clinical Trials. Registry and results database. Available from: https://clinicaltrials.gov/.
   Google Scholar
• Thai Clinical Trials Registry. Available from: www.clinicaltrials.in.th.
   Google Scholar
• Sri Lanka Clinical Trials Registry. Available from: trials.slctr.lk/.
   Google Scholar
• Chinese Clinical Trials Registry. Available from: www.chictr.org.cn.
   Google Scholar
• Clinical Trials Registry-India. Available from: www.ctri.nic.in.
   Google Scholar
• Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3:722–727.
   PubMed Web of Science ®Google Scholar
• Navarro-Sanchez E, Altmeyer R, Amara A, et al. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep. 2003;4:723–728.
   PubMed Web of Science ®Google Scholar
• Randolph VB, Winkler G, Stollar V. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology. 1990;174:450–458.
   PubMed Web of Science ®Google Scholar
• Silva MC, Guerrero-Plata A, Gilfoy FD, et al. Differential activation of human monocyte-derived and plasmacytoid dendritic cells by West Nile virus generated in different host cells. J Virol. 2007;81:13640–13648.
   PubMed Web of Science ®Google Scholar
• Accapezzato D, Visco V, Francavilla V, et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med. 2005;202:817–828.
   PubMed Web of Science ®Google Scholar
• Jang CH, Choi JH, Byun MS, et al. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford). 2006;45:703–710.
   PubMed Web of Science ®Google Scholar
• Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide induced TNF-alpha gene expression by a non-lysosomotropic mechanism. J Immunol. 2000;165:1534–1540.
   PubMed Web of Science ®Google Scholar
• Omura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents. 2008;31:91–98.
   PubMed Web of Science ®Google Scholar
• Mastrangelo E, Pezzullo M, Burghgraeve TD, et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother. 2012;67:1884–1894.
   PubMed Web of Science ®Google Scholar
• Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of importin α/β-mediated import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443:851–856.
   PubMed Web of Science ®Google Scholar
• Tay MYF, Fraser JE, Chan WKK, et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5: protection against all 4 DENV serotypes by the inhibitor ivermectin. Antiviral Res. 2013;99:301–306.
   PubMed Web of Science ®Google Scholar
• Salgado D, Zabaleta TE, Hatch S, et al. Use of pentoxifylline in treatment of children with dengue hemorrhagic fever. Pediatric Infect Dis J. 2012;31:771–773.
   PubMed Web of Science ®Google Scholar
• Castro JE, Vado-Solis I, Perez-Osorio C, et al. Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever. Clin Dev Immunol. 2011. Article ID 370872. doi:10.1155/2011/370872
   Google Scholar
• Duyen HT, Ngoc TV, Ha do T. et al. Kinetics of Plasma Viremia and Soluble Nonstructural Protein 1 Concentrations in Dengue: Differential Effects according to Serotype and Immune Status. J Infect Dis. 2011;203:1292–1300.
   PubMed Web of Science ®Google Scholar
• Chappell D, Jacob M, Hofmann-Kiefer K, et al. Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx. Anesthesiology. 2007;107:776–784.
   PubMed Web of Science ®Google Scholar
• Chappell D, Dorfler N, Jacob M, et al. Glycocalyx protection reduces leukocyte adhesion after ischemia/reperfusion. Shock. 2010;34:133–139.
   PubMed Web of Science ®Google Scholar
• Li M, Losordo DW. Statins and the endothelium. Vascul Pharmacol. 2007;46:1–9.
   PubMed Web of Science ®Google Scholar
• Martinez-Gutierrez M, Castellanos JE, Gallego-Gomez JC. Statins reduce dengue virus production via decreased virion assembly. Intervirology. 2011;54:202–216.
   PubMed Web of Science ®Google Scholar
• Rothwell C, Lebreton A, Young NC, et al. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology. 2009;389:8–19.
   PubMed Web of Science ®Google Scholar
• Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke J Cereb Circ. 2002;33:2337–2341.
   Web of Science ®Google Scholar
• Klumpp KSD. Discovery and clinical evaluation of the nucleoside analog balapiravir (R1626) for the treatment of HCV infection. In: Kazmierski W, editor. Antiviral drugs: from basic discovery through clinical trials. Hoboken (NJ): John Wiley & Sons; 2011.
   Google Scholar
• Klumpp K, Leveque V, Le PS, et al. The novel nucleoside analog R1479 (4ʹ-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem. 2006;281:3793–3799.
   PubMed Web of Science ®Google Scholar
• Roberts SK, Cooksley G, Dore GJ, et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology. 2008;48:398–406.
   PubMed Web of Science ®Google Scholar
• Chen YL, Ghafar NA, Karuna R, et al. Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir. J Virol. 2014;88:1740–1747.
   PubMed Web of Science ®Google Scholar
• Malinoski FJ, Hasty SE, Ussery MA, et al. Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antiviral Res. 1990;13:139–149.
   PubMed Web of Science ®Google Scholar
• Schul W, Liu W, Xu HY, et al. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis. 2007;195:665–674.
   PubMed Web of Science ®Google Scholar
• Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C. Cochrane Database Syst Rev. 2005;4:CD005527.
   PubMedGoogle Scholar
• Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin treatment of hepatitis C. Nature. 2005;436:967–972.
   PubMed Web of Science ®Google Scholar
• Mehta A, Zitzmann N, Rudd PM, et al. Alpha-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Lett. 1998;430:17–22.
   PubMed Web of Science ®Google Scholar
• Courageot MP, Frenkiel MP, Dos Santos CD, et al. Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J Virol. 2000;74:564–572.
   PubMed Web of Science ®Google Scholar
• Rathore AP, Paradkar PN, Watanabe S, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res. 2011;92:453–460.
   PubMed Web of Science ®Google Scholar
• Durantel D. Celgosivir, an alpha-glucoside I inhibitor for the potential treatment of HCV infection. Curr Opin Investig Drugs. 2009;10:860–870.
   PubMedGoogle Scholar
• Watanabe S, Rathore AP, Sung C, et al. Dose- and schedule dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res. 2012;96:32–35.
   PubMed Web of Science ®Google Scholar
• Low JG, Ong A, Tan LK, et al. The early clinical features of dengue in adults: challenges for early clinical diagnosis. PLoS Negl Trop Dis. 2011;5:e1191.
   PubMed Web of Science ®Google Scholar
• Perry ST, Buck MD, Plummer EM, et al. An iminosugar with potent inhibition of dengue virus infection in vivo. Antiviral Res. 2013;98:35–53.
   PubMed Web of Science ®Google Scholar
• Plummer E, Buck MD, Sanchez M, et al. Dengue virus evolution under a host-targeted antiviral. J Virol. 2015;89:5592–5601.
   PubMed Web of Science ®Google Scholar
• Tang LIC, Ling APK, Koh RY, et al. Screening of anti-dengue activity in methanolic extracts of medicinal plants. BMC Comp Alt Med. 2012;12:3.
   PubMed Web of Science ®Google Scholar
• Lee SH, Tang YQ, Rathkrishnan A, et al. Effect of cocktail of four local Malaysian medicinal plants (Phyllanthus spp.) Against Dengue Virus 2. BMC Comp Alt Med. 2013;13:192.
   PubMed Web of Science ®Google Scholar
• Sarala N, Paknikar SS. Papaya extract to treat dengue: A novel therapeutic option? Ann Med Health Sci Res. 2014;4:320–324.
   PubMedGoogle Scholar
• Sood R, Raut R, Tyagi P, et al. Cissampelos pariera Linn: Natural source of potent antiviral activity against all four dengue virus serotypes. PLoS Negl Trop Dis. 2015;9:e0004255.
   PubMed Web of Science ®Google Scholar
• Zhang F, Kramer CV. Corticosteroids for dengue infection. Cochrane Database Syst Rev. 2014;7:Art. No.CD003488. doi:10.1002/14651858.CD003488.pub3.
   PubMed Web of Science ®Google Scholar
• Schul W, Yip A, Shi PY. Testing antiviral compounds in a dengue mouse model. Methods Mol Biol. 2013;1030:269–281.
   PubMedGoogle Scholar
• Zompi S, Harris E. Animal models of dengue virus infection. Viruses. 2012;4:62–82.
   PubMed Web of Science ®Google Scholar
• Thomas SJ. Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development. Hum Vaccin Immunother. 2013;9:1587–1590.
   PubMed Web of Science ®Google Scholar
• Sun W, Eckels KH, Putnak JR, et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis. 2013;207:700–708.
   PubMed Web of Science ®Google Scholar
• Whitehorn J, Nguyen Van VC, Simmons CP. Dengue human infection models supporting drug development. J Infect Dis. 2014;209(S2):S66–S70.
   PubMed Web of Science ®Google Scholar